Engagement and Clinical Impact of the Teleo Virtual Therapy Platform in Clinical Settings

October 19, 2026 updated by: David Hong, Stanford University

Engagement and Clinical Impact of the Teleo Virtual Therapy Platform

The research study will examine engagement in telehealth for children undergoing psychotherapy. Specifically, the pilot trial will examine examine patient engagement in Teleo, a virtual therapy platform specifically designed for psychotherapy with youth, as compared to standard video conferencing.

Study Overview

Status

Completed

Detailed Description

The research study will examine engagement in telehealth for children undergoing psychotherapy. The study in Phase I entails a pilot randomized trial with a goal to enroll children from 42 families and their therapists, examining patient engagement in Teleo, a virtual therapy platform specifically designed for psychotherapy with youth, as compared to standard video conferencing.

Engagement will be assessed using well-established measures - CIRS (modified) video coding (session 1), MTT-Y/MTTCG (sessions 1, 4) and attendance data (sessions 1-4). Clinicians in the study will deliver therapy to clients for 4 sessions, providing opportunity to measure temporal sustainment of any engagement differences.

Study Type

Interventional

Enrollment (Actual)

56

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • California
      • Stanford, California, United States, 94305
        • Stanford University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

5 years to 14 years (Child)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Receiving psychotherapy with a licensed professional on the Teleo platform
  • Likely have at least 12 sessions remaining.
  • Diagnosis of a mental health condition by a licensed clinician

Exclusion Criteria:

  • Not under treatment with provider using Teleo platform

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Teleo

Participants in this group will undergo therapy for 4 sessions using the Teleo virtual therapy video platform, sessions will be recorded and questionnaires and clinical data will be measured.

Therapist-led psychotherapy sessions implemented within the Teleo virtual therapy platform.

Active Comparator: Standard videoconferencing

Participants in this group will undergo therapy for 4 sessions using standard video platforms (e.g. zoom or other publicly available product), sessions will be recorded and questionnaires and clinical data will be measured.

Therapist-led psychotherapy sessions implemented in standard (non-Teleo) video platform

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Child Involvement Rating Scale (CIRS)
Time Frame: Week 1

The Child Involvement Rating Scale (CIRS) is a 10-item observer-rated measure of child engagement in therapy. Each item is rated on a 6-point Likert scale ranging from 0 (No presence) to 5 (A great deal). Six items (initiating discussion, suggesting task changes, enthusiastic participation, self-disclosure, asking questions, and elaboration) assess positive therapeutic engagement, where a higher score indicates greater engagement. The four remaining items (withdrawal, avoidance, distraction, and oppositionality) assess disengagement-related behaviors, where a higher score indicates greater disengagement. The six engagement items are directly scored (a rating of 0 is scored as 0, and a rating of 5 is scored as 5). The four disengagement items are reverse-scored (a rating of 0 is scored as 5, and a rating of 5 is scored as 0). All 10 item scores are summed to produce a CIRS total score ranging from 0 to 50. Higher total scores indicate greater child engagement (better outcomes).

Week 1

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
My Thoughts About Therapy - Caregiver (MTT-CG)
Time Frame: Weeks 1 and 4

The My Thoughts About Therapy Questionnaire - Caregiver Version (MTT-CG) is a 35-item questionnaire with 5 subscales, each with 7 items, that represent the multidimensional REACH framework for characterizing treatment engagement: Relationship, Expectancy, Attendance, Clarity, and Homework (Becker et al., 2018). Items are rated on a 4-point Likert-scale from 0 ("strongly disagree") to 3 ("strongly agree").

To score the MTT, each item is assigned a numerical value from 0-3, where 0 = strongly disagree, 1 = disagree, 2 = agree, and 3 = strongly agree. For each subscale add the numerical values for each of the 7 items together. Thus, the highest subscale score possible is 21, the lowest 0. The total score is calculated as the sum of the 5 subscale scores, with a maximum possible score of 105 and a minimum possible score of 0.

Weeks 1 and 4
My Thoughts About Therapy - Youth Version (MTT-Y)
Time Frame: Weeks 1 and 4

The My Thoughts About Therapy Questionnaire - Youth Version (MTT-Y) is a 35-item questionnaire with 5 subscales, each with 7 items, that represent the multidimensional REACH framework for characterizing treatment engagement: Relationship, Expectancy, Attendance, Clarity, and Homework (Becker et al., 2018). Items are rated on a 4-point Likert-scale from 0 ("strongly disagree") to 3 ("strongly agree").

To score the MTT, each item is assigned a numerical value from 0-3, where 0 = strongly disagree, 1 = disagree, 2 = agree, and 3 = strongly agree. For each subscale add the numerical values for each of the 7 items together. Thus, the highest subscale score possible is 21, the lowest 0. The total score is calculated as the sum of the 5 subscale scores, with a maximum possible score of 105 and a minimum possible score of 0.

Weeks 1 and 4
Psychotherapy Session Attendance
Time Frame: Weeks 1-4

Clinicians recorded attendance for each of the 4 scheduled therapy sessions (Weeks 1-4) on an attendance form, categorizing each session as attended on time, attended late (10+ minutes), rescheduled/cancelled, no-show, or treatment dropout. The reported value is the number of sessions attended on time in each arm, calculated as a single pooled proportion across participants: the number of sessions attended on time divided by the number of scheduled sessions for all participants in that arm. Values range from 0 to 1, with higher values indicating better attendance.

Weeks 1-4

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: David S Hong, MD, Stanford University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2024

Primary Completion (Actual)

August 15, 2025

Study Completion (Actual)

September 15, 2025

Study Registration Dates

First Submitted

April 8, 2024

First Submitted That Met QC Criteria

April 8, 2024

First Posted (Actual)

April 15, 2024

Study Record Updates

Last Update Posted (Actual)

November 12, 2026

Last Update Submitted That Met QC Criteria

October 19, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 73203
  • R42MH136878 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe